188 related articles for article (PubMed ID: 38395948)
21. Immunological responses to adjuvant vaccination with combined CD1c
Bloemendal M; Bol KF; Boudewijns S; Gorris MAJ; de Wilt JHW; Croockewit SAJ; van Rossum MM; de Goede AL; Petry K; Koornstra RHT; Figdor C; Gerritsen WR; Schreibelt G; de Vries IJM
Oncoimmunology; 2022; 11(1):2015113. PubMed ID: 36524210
[TBL] [Abstract][Full Text] [Related]
22. Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised "proof-of-principle" phase II study.
de Rosa F; Ridolfi L; Ridolfi R; Gentili G; Valmorri L; Nanni O; Petrini M; Fiammenghi L; Granato AM; Ancarani V; Pancisi E; Soldati V; Cassan S; Riccobon A; Parisi E; Romeo A; Turci L; Guidoboni M
J Transl Med; 2014 Jul; 12():209. PubMed ID: 25053129
[TBL] [Abstract][Full Text] [Related]
23. HEV-associated dendritic cells are observed in metastatic tumor-draining lymph nodes of cutaneous melanoma patients with longer distant metastasis-free survival after adjuvant immunotherapy.
Bravo AI; Aris M; Panouillot M; Porto M; Dieu-Nosjean MC; Teillaud JL; Barrio MM; Mordoh J
Front Immunol; 2023; 14():1231734. PubMed ID: 37691949
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant vemurafenib in resected, BRAF
Maio M; Lewis K; Demidov L; Mandalà M; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Yan Y; Schadendorf D;
Lancet Oncol; 2018 Apr; 19(4):510-520. PubMed ID: 29477665
[TBL] [Abstract][Full Text] [Related]
25. Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial.
Boudewijns S; Bloemendal M; de Haas N; Westdorp H; Bol KF; Schreibelt G; Aarntzen EHJG; Lesterhuis WJ; Gorris MAJ; Croockewit A; van der Woude LL; van Rossum MM; Welzen M; de Goede A; Hato SV; van der Graaf WTA; Punt CJA; Koornstra RHT; Gerritsen WR; Figdor CG; de Vries IJM
Cancer Immunol Immunother; 2020 Mar; 69(3):477-488. PubMed ID: 31980913
[TBL] [Abstract][Full Text] [Related]
26. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
Slingluff CL; Petroni GR; Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Hibbitts S; Teates D; Neese PY; Grosh WW; Chianese-Bullock KA; Woodson EM; Wiernasz CJ; Merrill P; Gibson J; Ross M; Engelhard VH
J Clin Oncol; 2003 Nov; 21(21):4016-26. PubMed ID: 14581425
[TBL] [Abstract][Full Text] [Related]
27. Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients.
Frankel AE; Coughlin LA; Kim J; Froehlich TW; Xie Y; Frenkel EP; Koh AY
Neoplasia; 2017 Oct; 19(10):848-855. PubMed ID: 28923537
[TBL] [Abstract][Full Text] [Related]
28. Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy.
Bloemendal M; van Willigen WW; Bol KF; Boers-Sonderen MJ; Bonenkamp JJ; Werner JEM; Aarntzen EHJG; Koornstra RHT; de Groot JWB; de Vries IJM; van der Hoeven JJM; Gerritsen WR; de Wilt JHW
Ann Surg Oncol; 2019 Nov; 26(12):3945-3952. PubMed ID: 30830540
[TBL] [Abstract][Full Text] [Related]
29. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.
Eggermont AMM; Kicinski M; Blank CU; Mandala M; Long GV; Atkinson V; Dalle S; Haydon A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; Krepler C; Ibrahim N; Marreaud S; van Akkooi A; Robert C; Suciu S
JAMA Oncol; 2020 Apr; 6(4):519-527. PubMed ID: 31895407
[TBL] [Abstract][Full Text] [Related]
30.
Alameddine J; Godefroy E; Papargyris L; Sarrabayrouse G; Tabiasco J; Bridonneau C; Yazdanbakhsh K; Sokol H; Altare F; Jotereau F
Front Immunol; 2019; 10():143. PubMed ID: 30787928
[TBL] [Abstract][Full Text] [Related]
31. Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients.
Peters BA; Wilson M; Moran U; Pavlick A; Izsak A; Wechter T; Weber JS; Osman I; Ahn J
Genome Med; 2019 Oct; 11(1):61. PubMed ID: 31597568
[TBL] [Abstract][Full Text] [Related]
32. Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.
Borgers JSW; Burgers FH; Terveer EM; van Leerdam ME; Korse CM; Kessels R; Flohil CC; Blank CU; Schumacher TN; van Dijk M; Henderickx JGE; Keller JJ; Verspaget HW; Kuijper EJ; Haanen JBAG
BMC Cancer; 2022 Dec; 22(1):1366. PubMed ID: 36585700
[TBL] [Abstract][Full Text] [Related]
33. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.
Schadendorf D; Ugurel S; Schuler-Thurner B; Nestle FO; Enk A; Bröcker EB; Grabbe S; Rittgen W; Edler L; Sucker A; Zimpfer-Rechner C; Berger T; Kamarashev J; Burg G; Jonuleit H; Tüttenberg A; Becker JC; Keikavoussi P; Kämpgen E; Schuler G;
Ann Oncol; 2006 Apr; 17(4):563-70. PubMed ID: 16418308
[TBL] [Abstract][Full Text] [Related]
34. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.
Saberian C; Amaria RN; Najjar AM; Radvanyi LG; Haymaker CL; Forget MA; Bassett RL; Faria SC; Glitza IC; Alvarez E; Parshottam S; Prieto V; Lizée G; Wong MK; McQuade JL; Diab A; Yee C; Tawbi HA; Patel S; Shpall EJ; Davies MA; Hwu P; Bernatchez C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021033
[TBL] [Abstract][Full Text] [Related]
35. Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697).
Butterfield LH; Zhao F; Lee S; Tarhini AA; Margolin KA; White RL; Atkins MB; Cohen GI; Whiteside TL; Kirkwood JM; Lawson DH
Clin Cancer Res; 2017 Sep; 23(17):5034-5043. PubMed ID: 28536308
[No Abstract] [Full Text] [Related]
36. Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma.
Storkus WJ; Maurer D; Lin Y; Ding F; Bose A; Lowe D; Rose A; DeMark M; Karapetyan L; Taylor JL; Chelvanambi M; Fecek RJ; Filderman JN; Looney TJ; Miller L; Linch E; Lowman GM; Kalinski P; Butterfield LH; Tarhini A; Tawbi H; Kirkwood JM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34782430
[TBL] [Abstract][Full Text] [Related]
37. Both living and dead Faecalibacterium prausnitzii alleviate house dust mite-induced allergic asthma through the modulation of gut microbiota and short-chain fatty acid production.
Hu W; Lu W; Li L; Zhang H; Lee YK; Chen W; Zhao J
J Sci Food Agric; 2021 Oct; 101(13):5563-5573. PubMed ID: 33709404
[TBL] [Abstract][Full Text] [Related]
38. CD56
Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
Front Immunol; 2019; 10():14. PubMed ID: 30761123
[TBL] [Abstract][Full Text] [Related]
39. Dendritic cell vaccination in melanoma patients: From promising results to future perspectives.
Boudewijns S; Bloemendal M; Gerritsen WR; de Vries IJ; Schreibelt G
Hum Vaccin Immunother; 2016 Oct; 12(10):2523-2528. PubMed ID: 27322496
[TBL] [Abstract][Full Text] [Related]
40. A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma.
Dasyam N; Sharples KJ; Barrow C; Huang Y; Bauer E; Mester B; Wood CE; Authier-Hall A; Dzhelali M; Ostapowicz T; Kumar R; Lowe J; Maxwell A; Burn OK; Williams GM; Carley SE; Caygill G; Jones J; Chan STS; Hinder VA; Macapagal J; McCusker M; Weinkove R; Brimble MA; Painter GF; Findlay MP; Dunbar PR; Gasser O; Hermans IF
Cancer Immunol Immunother; 2023 Jul; 72(7):2267-2282. PubMed ID: 36881133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
